Log in

Eisai News Headlines (OTCMKTS:ESALY)

$51.16
-0.08 (-0.16 %)
(As of 10/18/2019 01:08 AM ET)
Today's Range
$51.16
Now: $51.16
$51.21
50-Day Range
$48.96
MA: $50.49
$52.38
52-Week Range
$48.52
Now: $51.16
$96.16
Volume1,552 shs
Average Volume8,515 shs
Market Capitalization$14.66 billion
P/E Ratio25.71
Dividend Yield2.38%
Beta0.26

Headlines

Eisai (OTCMKTS ESALY) News Headlines

Source:
DateHeadline
Eisai Co., Ltd (OTCMKTS:ESALY) Given Average Rating of "Hold" by BrokeragesEisai Co., Ltd (OTCMKTS:ESALY) Given Average Rating of "Hold" by Brokerages
www.americanbankingnews.com - September 24 at 12:43 PM
Eisai (OTCMKTS:ESALY) Coverage Initiated at Jefferies Financial GroupEisai (OTCMKTS:ESALY) Coverage Initiated at Jefferies Financial Group
www.americanbankingnews.com - September 24 at 12:32 PM
FDA Approves Merck, Eisai Treatment for Advanced Endometrial CarcinomaFDA Approves Merck, Eisai Treatment for Advanced Endometrial Carcinoma
www.thestreet.com - September 19 at 3:31 PM
Merck Won ‘Groundbreaking’ Approval for Cancer Treatment in 3 Countries at OnceMerck Won ‘Groundbreaking’ Approval for Cancer Treatment in 3 Countries at Once
finance.yahoo.com - September 19 at 3:31 PM
Eisai to Present New 12-month Safety & Effectiveness Data from Phase 3 Lemborexant SUNRISE 2 Study and New Patient and Cohabitant Insights about Insomnia and Toll on Next-Day Functioning at World Sleep CongressEisai to Present New 12-month Safety & Effectiveness Data from Phase 3 Lemborexant SUNRISE 2 Study and New Patient and Cohabitant Insights about Insomnia and Toll on Next-Day Functioning at World Sleep Congress
www.prnewswire.com - September 19 at 1:02 PM
Biogen Scraps 2 More Studies In Alzheimer's Disease — And Shares PopBiogen Scraps 2 More Studies In Alzheimer's Disease — And Shares Pop
finance.yahoo.com - September 14 at 3:00 PM
Japan’s GHIT ramps up fight against neglected diseasesJapan’s GHIT ramps up fight against neglected diseases
finance.yahoo.com - August 27 at 10:50 AM
Eisais Cancer Drug Combo Gets Breakthrough Therapy Designation For Liver CancerEisai's Cancer Drug Combo Gets Breakthrough Therapy Designation For Liver Cancer
feeds.benzinga.com - July 23 at 9:43 AM
Watch These 4 Japanese Drugmakers With Big Coming EventsWatch These 4 Japanese Drugmakers With Big Coming Events
finance.yahoo.com - July 5 at 10:12 AM
Xencor (XNCR) Jumps: Stock Rises 7.4%Xencor (XNCR) Jumps: Stock Rises 7.4%
finance.yahoo.com - July 2 at 10:20 AM
Eisais Fycompa shows positive effect in late-state epilepsy studyEisai's Fycompa shows positive effect in late-state epilepsy study
seekingalpha.com - June 25 at 5:22 PM
The Zacks Analyst Blog Highlights: Eisai, Martin Marietta and Columbia SportswearThe Zacks Analyst Blog Highlights: Eisai, Martin Marietta and Columbia Sportswear
finance.yahoo.com - June 25 at 9:28 AM
Why Alzheimer's Treatment Hopes Endure Despite High-Profile Drug FailuresWhy Alzheimer's Treatment Hopes Endure Despite High-Profile Drug Failures
finance.yahoo.com - June 14 at 12:19 PM
Patrick Coyle appointed Vice President and CFO of Eisai.Patrick Coyle appointed Vice President and CFO of Eisai.
seekingalpha.com - June 4 at 10:17 AM
Key Drugs in Merck’s Oncology PortfolioKey Drugs in Merck’s Oncology Portfolio
finance.yahoo.com - May 15 at 5:47 PM
CannTrust Holdings (CTST) in Focus: Stock Moves 6.1% HigherCannTrust Holdings (CTST) in Focus: Stock Moves 6.1% Higher
finance.yahoo.com - May 15 at 10:08 AM
Catalyst (CPRX) Q1 Loss Narrows, Firdapse Off to a Good StartCatalyst (CPRX) Q1 Loss Narrows, Firdapse Off to a Good Start
finance.yahoo.com - May 14 at 6:15 PM
Eisai teams up with ACTC in AlzheimersEisai teams up with ACTC in Alzheimer's
seekingalpha.com - May 10 at 10:16 AM
Alzheimers Clinical Trials Consortium Selects Elenbecestat and BAN2401 for Upcoming Clinical Studies on Prevention of Alzheimers DiseaseAlzheimer's Clinical Trials Consortium Selects Elenbecestat and BAN2401 for Upcoming Clinical Studies on Prevention of Alzheimer's Disease
www.prnewswire.com - May 10 at 8:45 AM
United Therapeutics Discontinues PAH Drug After Study FailsUnited Therapeutics Discontinues PAH Drug After Study Fails
finance.yahoo.com - April 9 at 11:03 AM
Zogenix Gets Refusal to File Letter From FDA for Seizure DrugZogenix Gets Refusal to File Letter From FDA for Seizure Drug
finance.yahoo.com - April 9 at 11:03 AM
Data Safety Monitoring Board Recommends Continuation Of Phase III Clinical Studies Of BACE Inhibitor Elenbecestat In Early Alzheimers DiseaseData Safety Monitoring Board Recommends Continuation Of Phase III Clinical Studies Of BACE Inhibitor Elenbecestat In Early Alzheimer's Disease
www.prnewswire.com - March 29 at 3:41 PM
In The Wake Of Biogens Alzheimers Failure, Who Do We Turn Our Attention To Now?In The Wake Of Biogen's Alzheimer's Failure, Who Do We Turn Our Attention To Now?
seekingalpha.com - March 25 at 5:37 PM
Nikkei hits five-week low on renewed fears of global slowdownNikkei hits five-week low on renewed fears of global slowdown
finance.yahoo.com - March 24 at 10:47 PM
Biogen Tanks, Drags Down Biotechnology Sector ETFsBiogen Tanks, Drags Down Biotechnology Sector ETFs
finance.yahoo.com - March 23 at 4:40 PM
Biogen and Eisai launch late-stage study of BAN2401 in AlzheimersBiogen and Eisai launch late-stage study of BAN2401 in Alzheimer's
seekingalpha.com - March 22 at 5:31 PM
Eisai Launches Confirmatory Late-Stage Trial Of Second Alzheimers Asset After SetbackEisai Launches Confirmatory Late-Stage Trial Of Second Alzheimer's Asset After Setback
finance.yahoo.com - March 22 at 5:31 PM
Analysts Digest Biogens Alzheimers Disappointment: There Isnt Much To Be Excited AboutAnalysts Digest Biogen's Alzheimer's Disappointment: 'There Isn't Much To Be Excited About'
finance.yahoo.com - March 22 at 5:31 PM
Biogen Skids On Alzheimer's Flop — And Unveils Yet Another StudyBiogen Skids On Alzheimer's Flop — And Unveils Yet Another Study
finance.yahoo.com - March 22 at 5:31 PM
Biogen stock price target cut to $247 from $341 at SVB LeerinkBiogen stock price target cut to $247 from $341 at SVB Leerink
finance.yahoo.com - March 22 at 10:33 AM
Biogen stock plummets 28% after company halts Alzheimer’s trialsBiogen stock plummets 28% after company halts Alzheimer’s trials
www.marketwatch.com - March 21 at 5:35 PM
Eisai down 28% on aducanumab failEisai down 28% on aducanumab fail
seekingalpha.com - March 21 at 5:35 PM
Why Eisai (ESALY) Could Be an Impressive Growth StockWhy Eisai (ESALY) Could Be an Impressive Growth Stock
finance.yahoo.com - March 15 at 10:46 AM
FDA to review Eisai and Imbrium Therapeutics NDA for lemborexantFDA to review Eisai and Imbrium Therapeutics' NDA for lemborexant
seekingalpha.com - March 11 at 10:13 AM
[$$] Pharma industry steels itself for no-deal Brexit[$$] Pharma industry steels itself for no-deal Brexit
finance.yahoo.com - February 26 at 10:52 AM
Eisai files for revised labeling for obesity med BelviqEisai files for revised labeling for obesity med Belviq
seekingalpha.com - February 25 at 5:29 PM
Eisai and Empatica Enter an Agreement to Co-Promote the Embrace2 Device for People Living With Epilepsy in the U.S.Eisai and Empatica Enter an Agreement to Co-Promote the Embrace2 Device for People Living With Epilepsy in the U.S.
www.prnewswire.com - February 19 at 10:10 AM
Eisai Co., Ltd. to Host Earnings CallEisai Co., Ltd. to Host Earnings Call
finance.yahoo.com - February 4 at 5:01 PM
5 Tokyo Stocks to Target in 20195 Tokyo Stocks to Target in 2019
finance.yahoo.com - January 9 at 5:07 PM
First candidate from Eisai/UCL partnership to enter clinic next quarterFirst candidate from Eisai/UCL partnership to enter clinic next quarter
seekingalpha.com - December 7 at 9:41 AM
[$$] Pharma ignores the squabbling and prepares for a hard Brexit[$$] Pharma ignores the squabbling and prepares for a hard Brexit
finance.yahoo.com - November 19 at 9:42 AM
Keytruda + Lenvima combo shows positive effect in Phase 1b/2 study in three tumor typesKeytruda + Lenvima combo shows positive effect in Phase 1b/2 study in three tumor types
seekingalpha.com - November 9 at 10:07 AM
Biogen: One More Time Around The Alzheimers BlockBiogen: One More Time Around The Alzheimer's Block
seekingalpha.com - October 29 at 4:01 PM
More On BAN2401, UnfortunatelyMore On BAN2401, Unfortunately
seekingalpha.com - October 26 at 10:04 AM
Biogens aducanumab shows long-term effect in early-stage Alzheimers studyBiogen's aducanumab shows long-term effect in early-stage Alzheimer's study
seekingalpha.com - October 26 at 10:04 AM
This experimental Alzheimer’s disease drug seemed promising — before the latest results left many unsureThis experimental Alzheimer’s disease drug seemed promising — before the latest results left many unsure
finance.yahoo.com - October 25 at 4:04 PM
Biogen/Eisai Alzheimers data suggests treatment effect related to drugBiogen/Eisai Alzheimer's data suggests treatment effect related to drug
finance.yahoo.com - October 25 at 9:52 AM
Eisai To Present New Research On Human Genetics And Drug Discovery At ASHG Conference 2018Eisai To Present New Research On Human Genetics And Drug Discovery At ASHG Conference 2018
www.prnewswire.com - October 16 at 8:16 AM
FDA OKs expanded use for Eisais seizure med FycompaFDA OKs expanded use for Eisai's seizure med Fycompa
seekingalpha.com - September 28 at 4:03 PM
Eisais Lenvima OKd in China for liver cancerEisai's Lenvima OK'd in China for liver cancer
seekingalpha.com - September 5 at 10:01 AM
This page was last updated on 10/18/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel